Inovio Pharmaceuticals
INO
110 hedge funds and large institutions have $22.2M invested in Inovio Pharmaceuticals in 2025 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 34 increasing their positions, 27 reducing their positions, and 13 closing their positions.
1,018% more call options, than puts
Call options by funds: $436K | Put options by funds: $39K
46% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 13
26% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 27
15% more capital inflows, than outflows
Capital inflows: $5.68M | Capital outflows: $4.94M
5% more funds holding
Funds holding: 105 → 110 (+5)
0.12% more ownership
Funds ownership: 36.97% → 37.09% (+0.12%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$1.33M |
| 2 |
BlackRock
New York
|
+$823K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$713K |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$495K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$438K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
-$1.2M |
| 2 |
Stonepine Capital Management
Bend,
Oregon
|
-$1.07M |
| 3 |
Highbridge Capital Management
New York
|
-$549K |
| 4 |
Renaissance Technologies
New York
|
-$394K |
| 5 |
UBS O'Connor
Chicago,
Illinois
|
-$393K |
INO Hedge Fund Activity: Q1 2025 in Review
110 of the 7,493 institutional investors tracked by Wall St. Rank reported a position in Inovio Pharmaceuticals (INO) for Q1 2025, worth a combined $22.2M — down 9.3% from $24.4M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new INO positions and 13 closed out — a net gain of 6 holders — while 34 added to existing stakes and 27 trimmed.
The largest buyer was Bank of America, adding an estimated $1.33M. The largest seller was AIGH Capital Management, exiting entirely with an estimated $1.2M sold.
- 110 institutional investors held Inovio Pharmaceuticals (INO) as of Q1 2025, up from 105 in Q4 2024.
- Funds reported $22.2M of Inovio Pharmaceuticals stock for Q1 2025, down 9.3% quarter-over-quarter.
- 19 funds opened new Inovio Pharmaceuticals positions in Q1 2025 and 13 closed out, a net change of +6 holders.
- The largest Inovio Pharmaceuticals buyer in Q1 2025 was Bank of America, an estimated $1.33M added.
- The largest Inovio Pharmaceuticals seller in Q1 2025 was AIGH Capital Management, an estimated $1.2M sold.
Based on aggregated 13F filings for Q1 2025.